Cancer Center News

CHOP researchers developed CDX0239-PBD, a novel antibody-drug conjugate that demonstrates exceptional effectiveness against cancers expressing the ALK protein, achieving durable tumor responses in preclinical models. This breakthrough could pave the way for new precision medicine treatments, enhancing patient outcomes and reducing the side effects associated with existing therapies.

A new program within the Cancer Center at Children’s Hospital of Philadelphia (CHOP) will support caregivers to safely and comfortably manage their child’s leukemia. It’s called Backpacks With Barbara, a first-of-its-kind initiative that will provide 300 custom-designed, kid-friendly and medically safe backpacks to patients at CHOP undergoing blinatumomab therapy, a cutting-edge immunotherapy used to treat B-cell acute lymphoblastic leukemia.

Dr. Haley Newman, an attending physician with the Cancer Center at Children's Hospital of Philadelphia (CHOP) received the Young Investigator Award from Hyundai Hope on Wheels at a recent ceremony with her peers and patients. She received a $300,000 grant which will aid in vital research for pediatric cancer.

Researchers at Children’s Hospital of Philadelphia revealed insights into optimizing chimeric antigen receptor T cell (CAR-T) therapy for solid pediatric tumors, offering a more complete understanding of how tumor biology and immunological barriers affect efficiency and safety.

Investigators at Children’s Hospital of Philadelphia, St. Jude Children’s Research Hospital, Dana Farber Cancer Institute, and the Children’s Oncology Group, unveiled for the first time that changes in certain genes affect an aggressive cancer, T-cell acute lymphoblastic leukemia, differently depending on genetic ancestry.

John Simpkins, Chief Administrative Officer of the Cancer Center at Children’s Hospital of Philadelphia, is this year’s recipient of the Alex’s Lemonade Stand Pitcher of Hope Award.

Researchers at Children’s Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common childhood cancer. Researchers suggest that the findings, published recently in JCO Precision Oncology, could help establish a new standard of care.

Researchers at Children’s Hospital of Philadelphia (CHOP) developed a longitudinal atlas of neuroblastoma, a common and potentially deadly childhood cancer, to gain deeper understanding into precise molecular mechanisms underlying why and how certain treatments eventually become ineffective.

New research from Children’s Hospital of Philadelphia (CHOP) offers insight into how a rare genetic condition called Beckwith–Wiedemann syndrome (BWS) affects the liver and may raise cancer risk.

The 3 South Playroom in CHOP’s Main Building officially reopened after a renovation funded by generous support from Dancing While Cancering, the Maddie Kramer Foundation.